xmt-1592
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2020 (NCT04396340)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
SLC34A2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315004 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04396340 | Phase 1/Phase 2 (Phase 2) | May 11, 2020 | IQVIA, Mersana Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IQVIA | For profit | 1 | 0 | 1 | 2020 |
| Mersana Therapeutics | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1